-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CI0E+XztGBB3K+5ahOe18VhKNR+WJAEPPK2SKM9P3BRVb9zPNzupWSwSEcIkO4t3
 +mOYHq1c0BbeAtRT3zs2Sg==

<SEC-DOCUMENT>0000950123-10-046016.txt : 20100507
<SEC-HEADER>0000950123-10-046016.hdr.sgml : 20100507
<ACCEPTANCE-DATETIME>20100507090621
ACCESSION NUMBER:		0000950123-10-046016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100507
DATE AS OF CHANGE:		20100507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10810293

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c00478e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in;font-family: 'Times New Roman',Times,serif">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): May 5, 2010</B></DIV>
<!-- /xbrl,dc -->
<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Delaware
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>000-52091
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>1900 Lake Park Drive<BR>
Suite 380, Smyrna, Georgia
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>&nbsp;<BR>30080</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(678) 384-7220</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B></B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --> </DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 7%">On May&nbsp;5, 2010 we issued a press release reporting our results of operations for the quarter
ended March&nbsp;31, 2010. A copy of the press release is attached to this Current Report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 7%">Exhibit&nbsp;99.1 Press Release
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 7%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: May&nbsp;7, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c00478exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Exhibit&nbsp;99.1
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><IMG src="c00478c0047801.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc. Announces First Quarter Financial Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, GA, May&nbsp;05, 2010 &#151; GeoVax Labs, Inc. (OTCBB: GOVXD)</B>, a biotechnology company that
creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for
the three months ended March&nbsp;31, 2010.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax reported a net loss of $690,789 for the three months ended March&nbsp;31, 2010, compared to
$861,509 for the same period in 2009. Net losses were partially offset by grant revenues of
$1,338,560 and $710,155 for each period, respectively, related to the Company&#146;s grant from the
National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of
March&nbsp;31, 2010, the Company reported cash balances totaling $2,603,108.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax President and CEO Robert T. McNally, PhD, said, &#147;Our research is progressing as we
anticipated. Our preventative HIV vaccine candidate has completed Phase 1 clinical trials in
humans, and is currently in a Phase 2a clinical trial being conducted and funded by the HIV Vaccine
Trials Network (HVTN). Patient enrollment is proceeding well, and at the current rate, we expect
results of this trial to be ready in 2011.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;The US Food and Drug Administration recently gave us permission to proceed with a Phase 1 clinical
trial for our therapeutic HIV vaccine candidate. This trial will focus on recently HIV- infected
individuals who started drug treatment during their first year of infection. The clinical trial
site is now preparing to initiate the enrollment of volunteers who meet the trial&#146;s criteria.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;McNally concluded, &#147;Looking ahead, I foresee great things for GeoVax as an enterprise. Our
shareholders have approved a reverse stock split, which became effective on April&nbsp;27, and as a
result our share price is now sufficient to make it possible for us to qualify to list our stock on
a major exchange. That will increase our visibility, which can often lead to greater liquidity.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Summarized financial information is attached. Further information concerning the Company&#146;s
financial position and results of operations are included in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus &#151; that leads to AIDS) and other infectious agents. Our goals include
developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under
GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and
effectiveness, and obtaining regulatory approvals to move the product forward. All preventative
Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA
and MVA vaccines have demonstrated the ability to raise anti-HIV immune responses as well as for
their safety. Successful results from all Phase 1 testing supported the initiation of the first
Phase 2 testing. GeoVax&#146;s Phase 2 human trial began in January&nbsp;2009 and will involve 225
participants at sites in the United States and South America. Recently the FDA granted permission
to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect
that GeoVax will grant manufacturing and distribution rights in several
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 1</B>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">global markets in return
for upfront fees, collaborative development agreements, and royalties on
sales and distribution revenues. Internal vaccine manufacturing and distribution will also be
considered by GeoVax. For more information, please visit www.geovax.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Forward-Looking Statements</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Certain statements in this document are &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act These statements are based on management&#146;s current
expectations and are subject to uncertainty and changes in circumstances. Actual results may differ
materially from those included in these statements due to a variety of factors, including whether:
GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely
manner, GeoVax&#146;s vaccines will be safe for human use, GeoVax&#146;s vaccines will effectively prevent
AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed,
GeoVax raises required capital to complete vaccine development, there is development of competitive
products that may be more effective or easier to use than GeoVax&#146;s products, GeoVax will be able to
enter into favorable manufacturing and distribution agreements, and other factors, over which
GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and
does not intend to do so. More information about these factors is contained in GeoVax&#146;s filings
with the Securities and Exchange Commission including those set forth at &#147;Risk Factors&#148; in GeoVax&#146;s
Form&nbsp;10-K.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Contact</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 50%">At The Investor Relations Group:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Investor Relations</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 50%">James Carbonara / Jason Strominger

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">or

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Public Relations</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 50%">Janet Vasquez / Robin O&#146;Malley

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">(212)&nbsp;825-3210

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 2</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>FINANCIAL TABLES FOLLOW</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 3</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">March 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,339</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,369</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">857</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">724</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,038</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,581</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(691</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(862</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.04</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.06</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Balance Sheet Information<BR>
(amounts in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">March 31,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Dec. 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,516</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">365</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,053</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">315</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">344</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">467</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,316</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">473</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">572</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,362</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,744</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,316</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Shares Outstanding*</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,653</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,633</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><I>*</I></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="text-align: justify"><I>Restated for 1:50 reverse stock split effected April&nbsp;27, 2010</I></DIV></TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c00478c0047801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c00478c0047801.gif
M1TE&.#EAP@!$`/?_`!U>F4F*M9R^U%&.NN+L\J;%V&"8OL[>ZFZAPS5XJ?3X
M^5V6O2YQI562NIJ\TH>PRXRTSB9IGGJHQ]3C[.OR];[4XM?D[I&WSR)FG=#@
MZ]_J\<+7Y;3.WD&%L3J`K92XT"=IH!I:E\S>ZDR,M]GF[A=<FC%UIZG&V1A7
MD[W3X>OR]&&9P+C1X-SH[\K<Z=WH\+K2X66;P!=9F<C;Z.CP]"ILHL38YMCF
M[DZ-MX.NR]KG[SA^K.7N\SZ"L'2EQ2!BF]'A[(2ORQQ<ET>*M3I_K+?0WRAL
MH:#`U1A8E;+,W=CE[L;8YH"MR5J5O)>[TM+AZT6(LSR"KD2%LF6<P:S(VGBG
MQB-FG6V?PY_`U1]BFQY@FA=?H,G<Z8JRSC!SI1A8EBMMHC=]K%:2O,?:Z&F>
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MR/;Y^A9=G5".N*K'V>_U]SR`KK'+W+#,W+/.W8BRS&B<P2QOI!U@FGRIQW&B
MPVB>PKG1X!=;F#1VI_#U]J'"UIN]TZ'"U1==FSA\JM7C[8&LROS\_76FQ<_?
MZQ]AFC!XJ'>GQ>WT]E./NR1GH%>4O(BSSL/7Y1I;ETF(LZ'!UM;C[BIPHCE_
MKJ[*W!YBG!=6D________R'Y!`$``/\`+`````#"`$0```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#,*]"<`23\Z&#+XTTBRI,F3*!]FP*,'!8!D
M*6/*G$DSHK\%=?K)N%"SIT^3_H(*'4I4*,EE(?3H":'II].G__S=&:1(025)
ME,Y=<K4KVA%FD9B80A!C00-H`X:`6LMVR`!H#1;$0&"*221F1Z+MVG3I'"5)
ME10H<G1GY$%F,OK5(6,8JF.,_F[Y4=#HQ:4B1QY<&;`#5AH`2.S4R<-'D*!`
M?/C@*5$BC^L]L&74F4U;!NP]KO.PQI,ZD&E/>>K800(@C9H=T*X\.,+BD@Y+
M?B*@^-CBL76(M_YTHC0CVK4548P`_T!1!P]J/'EDTUEOQPZ*]^_;KU\_6X9K
M0ZQ+X-G/OS]K0Z_)!LA\\P$R&VZ\!8*'(3R(D!,=.Q!BP0N=_''+=1CZ0T@F
ME+CB`"9$1/!)>:H%QQX*>O333TMVT*>;>8+PD0<=*'RB31H1Z/)*!SBL,I<Z
MO3!Q321$%DED#KU4P08V"Z1%A`EJ6,&.$!_)8%XY)<I0@A2$X$"'3A4L(H,,
MGT1`!"8.N$)))H0TAF%*=Q3RB"P7-`"+$'6D9J)[*JK8$B)TU&$('PKFQ$X-
M.ZQ2Q04%>'.)!9PTLH@SBA!R1V%&0334I8/\`0DCR_"@PSJ;#*-,#MU(P4`&
MC=C1#PII%/_R0"!T&#A::G4(`4L#%\CR2"%WO`E9(1KL(L$.60""VAYT\-GG
MBBUJJ1H=0M30`0+,6"."!LL40D@?;KX95&$YY%3'`W?,DD`:.NE9QWJ`[$$H
M(%GLL,TN&A02KK`)W='))1<,\4,=@93P[G3/OAIH"8'DT0\(0VP3S24$,.+'
MOOPF9,D/KMIQ2%1W)/(."174@LTK'/-FXL*!U/'#$!=<(DVP&0_D3R9<L/(*
M+GAX(@.-":^(2'F!`*+%--O$,D$E?V!<<T,</(B#TU)!(LDEXI!A`@![!&+(
MNW3(X`D>N)C#"A>9..V4'QH<(840^PF78L(HT"%O'@#H@XXWCT#_0O/3%MWQ
MRI=US/"05*60,(PH[>!2`A\_![J?$%*(HX$?4/UAP0.PY"F#'7,G;(<,,J8R
M`!86*/`WX!GI`$@_=JB!.45W++*.$P%H0QK8I-<!RP,6_%&3(Y0\8$0>>``=
MM!YTZ(>+%..0`(G:K%?D#QDYR2"`1OXX<TXM'?!<0K-TH&?$`Y0XDM(B!;QB
M)1VA)]R\(58@L,$B?52/$+A!551,4DM9Q$EJ1P]16$$_Y,.##%Y1@'"0Q!^/
M\,$G/%$'A`7-#LA+0Q4R$`J'_$$#1?B`!$3A`U0PX80HA(`U"-&30D3"%S'`
M1`JHAY`C)*8.,:#A181QCB"H@36(((\G_S[A@T?H4"'^4((8ZE`"5P5-1>73
MPPIF``F'^(,'/B38:O+#1?W@X1FB.&)&5!""U03B$A'Q`RQ<!0@=].0/0)@%
M`/!003L83!Y*$&-!-"`&W%@P:.6I@3(HH,=.(*!\0--#>Q;I'OB@P`X`2(1/
M-O&@`.CQ'R)X'1WDL+J:,((:^G#->_*P!S%H`"(*V,9H_IBP\NP`!I*$R`;X
M@8>.=<T0=$`"@799CGI4L2>#\()'$,&#PS6`<!QPS"`FT(15HB`XVU!`0[@`
M@B8^$8IX2``]6*@I`<P(=B5`00.B,8%D2.*<Y^0$+];)BPU$P1@_B<4>=-**
MAS3B"Z]*12&LX_\/#:Q@#XE!00E`P`6%#*(+W[RF'O*0!5L(SR8."*=BZ)`#
M0CI$$[%LX0_>DX5]-H06-\R!N)2PAA(@XB-Y@,`@#O*'!>"!E<_"8`R:,A%Z
MY"%%>_`")21RR8P\(#%[B$5#$F&%Z7B,7X[8AQ#FB0(\+,`@A!!#":X)13MP
MH*<#T80V3BH#,TA3?P*A`#[IT(:5+J0"B:'#"+`ZDT:LP1`J*L$Z"$(!5$R5
MJG2P@ALIX@],S),.NO@%6&V&DWX`8@(+N8,9"&>XI_W!!W#MAS8:,1`HR"!^
M\HO'QRHB"1JA`!"G'.Q`\*%)7U#O$5^*W>R>U@=6.`P/4C`,'[YT313_U".T
M%6'"#7N1$G_XP1*):%-$[J`*2ZBBDW<(`_Q"L`R%G")[XRA('PI!@49,@IN*
M(,`A&H$Y?VA"`SPXQ"&6T<F"*((&XB4`#Q[*D#Y<X;)\".U-J2J#`ES$#VH`
M'7-/4HD"#,`(/TB%+@S`@4DPY`XM8,4.K/`#*T0!`I3(GT!8<$.>($0!`%!*
M"`0HD$D40`I:>)40=-&,%O@!&>\*PS+\$8IHB*8]ON"F09+!`$38`0\>X(2$
M&Z((!O0C#Z(0"&:?A003R)@BG'"56MF:D$1$`@E\8-9\2`.`6K!WQ@/8`QWG
M4YX]-&"SPBBJ'2*@"(1089XX',D=HJ$-R#5+_SZMP<0$?E`^'QC&`O5H%AYR
ML*]$9&,/=@Q`1A\R@\NR0R!454PT,`(#H`*C)!1X12T_,B@9?8D.GNA!)@X"
M`T3DX3TDHN,H`;$)@5P@,3*HP$$<80*/`(($__C#"I)':4+1L25YF-)'FM"8
M#-!(#WM0-4'\@8"T,N"7$2$$'V`G$"<^$1`$P(@#$@.(`R#$$9?@P"ZVS6UN
M<P`&Q2#((D"0UH$B0!D?6,$/K)D'+WAT("G(`U?K0(0@C",'89A-E>CQCTXD
MA0Y1*.\$+IV`2S4`#Z\J02IF084DT.(5WW0B'5;@IB,X#)+%A#=3`<&)BN09
M%@)AR1-=0E.+L*(.2O_!+4'N$`/3N/SE+[=")01R!\L:%@#6R*@_"E&`$'PI
M#P9HS"$`X:H\K*$%?[N#!8CPUWI0X!_8>)#*HV*`U]4AF4Y`>(L^(-B!#.(2
M^<@)%"F^\G]^Q`V_7`8:7+4'*EB$'8*HA4!@,_(0//TB04"Y'AYQ$!HT*]$J
MPH-]_^$-A]%!#9LUR"-2X2H96$`@?1A!3O;0C=42Y`]-^(9BX-%/PK&A()5(
M"@I^H(A.`"(^-D!()MI`VXF'RQ(,^-(>@GZ'#F2/[!XO`4VW40]G/XL.&<`(
M8@S[A(-0@F"!2+[RE2]V&2#C'\'\4CUVFI!+$"[H_]#`I8E@>?.:X-*2\,?_
M8O4@!`,/Q`FH%NE/%8,%A5!@/!_!/4&2$0*V8^$"?S7"NR=RASD\8"!_4'@P
M!0@(@!%%,$][8`L'T0+94`"RD`(0&($5(`LKT'C1]0@G!0C;L!#^8`]!Q`X=
M=&K]@`A*L!#6UP][P`S_L`&H=@\`:`0=TPAWD%]VP`#=9Q`7\"#R1Q"%ER+K
MH3![51'T$`7J8S,.8`@P!0<T<!&4X!%T8%H&00.DH!`#IQ/;,PS4QG<+80M[
MH!0\X`^@$!K@4%X%X0<P2`>6=`PPB`2P,#ME\"#0X`^-L"(RH((+P0,A$'\8
MXP_;X#!*@8)'<!'2$`+[MQ$%\#,)`PA08%84H0AI_X`B`,`(!D&&!+$.7Z(]
M_T`+PI$&'31L&<`*K8`*J)`#0P`Z=$`",R@:IL`0-]$L1A`LXW!#:.0/`?`E
MWV!M`Z<',B`"#/$'5M`B.T@0?@`/K3<%.S81DT`$I880EX`!AA`_>=`*3!85
MLV`NSQ<1!W")VY-WJE40+M`S^4%KS-,"A%!4=0`!K.@#S1(!F+,(_P8-_W`(
M)X4$7J`^OL8\C[<0@Y!?KI<03B!V=+"!%<$#F-!Q"K$(OF`(K],G>=`%E-@0
ME/`Z**`-,P<1V6B%_Y"#H[=__K`",N!(\.%IR9"*=%"`'#@`S0(&P>(/5Y`3
M*'`(((6""O@/-X`$>E`'J?^W$!M3-\$X$!J`!J%3![LP$?[P!%109NU5!@Q`
M:RM2`I@P:)H"#3D!"`%P9`QQD9A(81^1CQO1!"VS2P-2!84Q`LV2#3=8$$2%
M`E_`>0)!":D%!5;0$C_@4=+P"3=9!0RA!)?6D_]@"=E`.#EA!Z`5$:$P`8GG
M$(E0`%8P6RIB"*\P=0\Q=-.1!\'`B%=YB=%%`Z8H?_[0`-M`"9PP"J(Y"H_0
M"(8A`&F5DPD1-3HQ>/]P"XOU$8TG4C0W.'J0!>:'$/Y@`'NY+WWU5Z#0``]B
M!%W'BH70"0^Y$,90`&J@0.1!!Q=@"1-1`'>5!_+P59>I$]&E6%\""!LP$'=0
M`33_I)DC"`:ED!"D4%3OT5P#L0F)T2>`L(0#$0T.@T,/:0,+V8\%<087IPV+
MH`IN('L-D)PV0Z`\Y@I#4![ED0TI8)6L>`H(]V,1``-7AA!/@)D"L0[S9`<A
M4`:&8:"_J1CZ4)$%00'?AX)V=GGY!46KX":A``*RUPP5&A4S4']C%RZ'``"@
M(P/\]@\\H*,_=@%.<P=-8Q)WP`FL4$VFL0/T<);](@J3UCP,X`0D,`E_X`=8
MFJ5^0`BR@*%1009P)1JSH`'I4!1#01",D`J$DP4%@)Q240E8``#9$P'8.1#*
M\)YU4'P%<0F?]F/ZL`3`XEL$X`/"T2?Z*1!_\`JODP<2_]`8KM"%NK@$!7$'
MF<`#BS`(T[@0B2`"P<`.;[`%V6`+=9I8XP`([XEI>R`$5E`#K-JJ-0`+J:`B
MF"@0BM`!4R50=5`#/1`%O-JKO#H-F*`"`T$"]?`@>/`)"6`&;8`$M%8':$!]
M!:$)_P8.EKD1N6`()S4:/V`./0`&S3,=%:2'-H,*AI<`5^8/#W!Q```#%$`!
M0,`"*9`,3GH2A2`"59`%6U`'HO`"!BH0.@`*>`!HK](BNS0?3C2K`A$*OG!K
M=4,;#DL;?``+,J8#8$!KHE$'1/<1GL``D+D1"!`O2:";U/"MS#,;OP8(AC`$
M`+!K!%$$*/=9&4<0@S`"72@#^?\:!;E``YE:$<?0`D[P?35P`3Q@H(XP`SB`
M`JJQ!P^[M$P4`*MS!S#@!B50#DK+M!#K`@2A`$$0`GQ0`K(A+0#`"H58$)10
M`F@@G0G!`[Y`!S)R(/L!!BS@!TT@(]IPGH-0`.40''P@5`<Q"2!@"&K0!910
MK8YQ,V-P"D0P`DZ@`S-:$/ZP##`0!/`P#410N99[N94;!][027^0`76"N:`[
M#4VP8@2A"45@"E"P`U!@"C"0F_VR`.W'@9)0`#%@!LC!"B*`E*7`!OJP`Q(`
M!)'@!6%`!!Z`!6K#""W0N!RH`'ZP4O-Z$7=`"C:`##EP!.M`"D68$/[0!]S;
MO=[;O7?_X`A4\[WDVP>7HIO@HBEZ%!3I:Q#<VRF$T;TI00F7P`/CT`=D0!.W
M\`L:<``S4$Z%@*FB-<`3D0DDH`'W\`(FV1,:D@C%0`H*D`@70\`4S!`T\`(V
MT`*R,)2%6QCM6\$@[+BJ,RXA7,(F?,(HG,(JO,(LW,(N_,(P',,G81@[&Q4U
M+,,^,0@?$`N&40:LH`B)``$'P`/S()]W@`7C$"P"D`N&P0@0``R&$0X0<`/_
MD`*L@`JMD`N4)1"<$`P,T`'5T*\2L0&]X*`X3!$J(`BG,!+^X`5Z,`CGL`76
M<`-R+!`9L`7M]P<`@%A1$0-;T`](N0M;X`+^<$"Z8`2"0`=N_T0`==`&X[``
M6R"D)P$#S'##9SP#?``$B/H)!O`/P)`'/%`)=9`+_W`'^@`&F#,#8&!6%F`'
M`Q`"6[P-=L`(I6`'I\"]&5`'EL0,AM!<_E`%C"$0A*`$DN@/E!!M"@`#!3`!
M-,,(+$`-FP5!MK`)570'.L`(_M`"E?`(2:`#;/P(MF`#2&D,%5``.G",9VQJ
M>W`!8S`&Z&=?"Q`"J@`)2'`-_W``@?"=_C``#B`0CN`%*Z!]UG8'"0`&_G`.
M?``#&Y$`$1">SV``)"`,43$0QI`''_`/R2`(*<`#=+"Z=,`*_T`":)`-;<`'
MLN`/$"`#40``J:``%,`'FZ``=)`*H/^``H8P"O[`#'8P!"!@#JJP"$8`#^Y`
M#-&5SC9#EG3@&C]S`W=@!3V@(?5S!SOP"L&2"4+`GM%`!Z7@!X!@7PJ`!%?P
M#^20!]$6%2;``$$1I\\0`N/0&$W-!/ZP"@77"+O@!S4'#:%@!=`P"'<0!$>0
M`7S``OY``;XP"H6V#$I0`LQP!TN`!Q9``'B0!(Z@`7Q`#YNP!1PP"$K@S48M
M$,*@!0$P":7`"`V`!,Y`"N<8%40`#[*`!WIZ`K'U#PH@!&G@#2=@R_^@`WA0
M#?^P"@#P4,L`"-PP%?]P##J``X*`#S83`)A`"7OP>#0@`,$`#7"`!920!\$W
M$+V0!9;W``#_0`C```A5=`:(L`@?``<]T`%#8`0I<`RK4`=6(-B=+1#)L`>Q
MZP]MX`7^<`E\D'K^T`VI``*65,IMH&K^X`,RT`818`4A$`7^$`MX0`E-;4G^
MH`!#4`X\L`GQD'$3(`BN0!"MX`5K,`!R")V,X"#GH`1Y,`K%/0/%P`9&,!(4
M<`E^$`4#T`=-\`HC$0PUX`@^8`238`FC<``*,`D__0#$8&WSO0O$,%?_L`AU
MP`W_``$E()\04`Z&$%H$D`72J02"0`N<L@I(4`A3@`2)0`$R``)7T`"(P`<G
M\`^2P`?M``-%P`!9((D#40""(`.2\`]C0`P50`KP``B3H`DR$`,ZIM``@,`(
MU<`'PY"-4\`(="``A"`$]70':1`#A%<"*4`)/>`+D)`*"*``9Q`(5#S?5``/
M7Y4,4#!7#[``W'0)`5#)4=$+J]@'3.`+[`4#.'`(/K#&+3`"(Q`%`>`$[/D/
M+;`&?&`(4S"%!*$#0T`.`N$'S=`/!A`$32`\3Q"@#=`)T%<+_8`$2;P,(T``
<A3`"B'7NAG,'/6<'HE!%&A`%G_`*,Y"I`0$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
